The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDNL.L Regulatory News (DNL)

  • There is currently no data for DNL

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Director/PDMR Shareholding

5 Aug 2019 12:27

RNS Number : 9212H
Diurnal Group PLC
05 August 2019
 

5 August 2019

 

Diurnal Group plc

("Diurnal" or the "Company")

 

Grant of Deferred Share Awards

Director and PDMR Dealings

 

Diurnal Group plc (AIM: DNL), the specialty pharmaceutical company targeting patient needs in chronic endocrine (hormonal) diseases, announces the following deferred bonus share awards over ordinary shares of 5 pence ("Ordinary Shares") in Diurnal were granted under the Diurnal Group plc Long Term Incentive Plan (the "Plan") to persons discharging managerial responsibilities ("PDMR") in respect of the bonus due for the financial year ended 30 June 2019:

 

PDMR

Total number of shares under award

Type of award

Martin Whitaker

143,443

Deferred bonus share

Richard Bungay

86,066

Deferred bonus share

Richard Ross

30,256

Deferred bonus share

 

Under the rules of the Plan, up to 50% of the annual bonus payable to the senior management team are settled in deferred share bonus awards. Annual bonuses are payable at the sole discretion of the Remuneration Committee on the basis set out in the 2018 annual report. The bonus performance criteria for 2018/2019 included clinical and commercial milestones. The deferred bonus share awards will ordinarily vest on the first anniversary of their grant, subject to the grantee's continued service. The awards were granted under award agreements that incorporated the terms of the Plan. No consideration is due to be payable on vesting.

 

This notification is made in accordance with the Market Abuse Regulation.

 

 

For further information, please visit www.diurnal.co.uk or contact:

Diurnal Group plc

+44 (0)20 3727 1000

Martin Whitaker, Chief Executive Officer

Richard Bungay, Chief Financial Officer

Panmure Gordon (UK) Limited (Nominated Adviser and Joint Broker)

+44 (0) 20 7886 2500

Corporate Finance: Freddy Crossley, Emma Earl

Corporate Broking: James Stearns

Cantor Fitzgerald Europe (Joint Broker)

+44 (0) 20 7894 7000

Corporate Finance: Phil Davies, Will Goode, Michael Boot

Healthcare Equity Sales: Andrew Keith

FTI Consulting

+44 (0)20 3727 1000

Simon Conway

Victoria Foster Mitchell

Notes to Editors

 

About Diurnal Group plc

Founded in 2004, Diurnal is a UK-based specialty pharma company developing high quality products for the global market for the life-long treatment of chronic endocrine conditions, including Congenital Adrenal Hyperplasia and Adrenal Insufficiency. Its expertise and innovative research activities focus on circadian-based endocrinology to yield novel product candidates in the rare and chronic endocrine disease arena.

 

For further information about Diurnal, please visit www.diurnal.co.uk

 

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

Martin Whitaker

2

 

Reason for the notification

 

a)

 

Position/status

 

Chief Executive Officer

b)

 

Initial notification /Amendment

 

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

Diurnal Group plc

b)

 

LEI

 

213800I2HNUNZN1LDH29

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

a)

 

Description of the financial instrument, type of instrument

Ordinary Shares of 5 pence each in Diurnal Group plc

Identification code

GB00BDB6Q760

b)

 

Nature of the transaction

 

Grant of nil cost awards under the Diurnal Group plc Long Term Incentive Plan as follows:

 

Deferred bonus award over 143,443 ordinary shares.

 

The deferred bonus award will ordinarily vest on the first anniversary of their grant subject to continued service.

 

c)

 

Price(s) and volume(s)

Price(s)

Volume(s)

£nil

143,443

d)

 

Aggregated information

- Aggregated volume

143,443

- Price

£nil

e)

 

Date of the transaction

 

5 August 2019

f)

 

Place of the transaction

 

Outside a trading venue

 

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

 Richard Bungay

2

 

Reason for the notification

 

a)

 

Position/status

 

Chief Financial Officer

b)

 

Initial notification /Amendment

 

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

Diurnal Group plc

b)

 

LEI

 

213800I2HNUNZN1LDH29

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

a)

 

Description of the financial instrument, type of instrument

Ordinary Shares of 5 pence each in Diurnal Group plc

Identification code

GB00BDB6Q760

b)

 

Nature of the transaction

 

Grant of nil cost awards under the Diurnal Group plc Long Term Incentive Plan as par value options as follows:

 

Deferred bonus award over 86,066 ordinary shares.

 

The deferred bonus award will ordinarily vest on the first anniversary of their grant subject to continued service.

 

c)

 

Price(s) and volume(s)

Price(s)

Volume(s)

£nil

86,066

d)

 

Aggregated information

- Aggregated volume

86,066

- Price

£nil

e)

 

Date of the transaction

 

5 August 2019

f)

 

Place of the transaction

 

Outside a trading venue

 

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

 Richard Ross

2

 

Reason for the notification

 

a)

 

Position/status

 

Chief Scientific Officer

b)

 

Initial notification /Amendment

 

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

Diurnal Group plc

b)

 

LEI

 

213800I2HNUNZN1LDH29

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

a)

 

Description of the financial instrument, type of instrument

Ordinary Shares of 5 pence each in Diurnal Group plc

Identification code

GB00BDB6Q760

b)

 

Nature of the transaction

 

Grant of nil cost awards under the Diurnal Group plc Long Term Incentive Plan as par value options as follows:

 

Deferred bonus award over 30,256 ordinary shares.

 

The deferred bonus award will ordinarily vest on the first anniversary of their grant subject to continued service.

 

 

c)

 

Price(s) and volume(s)

Price(s)

Volume(s)

£nil

30,256

d)

 

Aggregated information

- Aggregated volume

30,256

- Price

£nil

e)

 

Date of the transaction

 

5 August 2019

f)

 

Place of the transaction

 

Outside a trading venue

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
DSHSSDFFIFUSEEA
Date   Source Headline
9th Jan 20187:00 amRNSPositive results from Alkindi food matrix study
9th Jan 20187:00 amRNSBusiness Update and Notice of Interim Results
5th Jan 20185:06 pmRNSIssue of Equity
5th Jan 20185:04 pmRNSReplacement - Director Dealings
5th Jan 20181:19 pmRNSDirector Dealings
19th Dec 201712:53 pmRNSHardman Research: Alkindi®: On route to Europe
15th Dec 201712:50 pmRNSDiurnal receives positive CHMP opinion for Alkindi
15th Dec 201712:11 pmRNSCHMP positive opinion for Alkindi® (Infacort®)
8th Dec 201711:30 amRNSTotal Voting Rights
29th Nov 201712:20 pmRNSDirector/PDMR Shareholding
21st Nov 201712:00 pmRNSResult of AGM
9th Nov 20176:19 pmRNSDirector Dealing and Issue of Equity
8th Nov 201712:00 pmRNSDirector/PDMR Shareholding
13th Oct 20179:00 amRNSPosting of Annual Report and AGM Notice
15th Sep 20177:00 amRNSInfacort® data published in Clinical Endocrinology
14th Sep 20177:15 amRNSHardman Research: Ready to press the button
7th Sep 20172:51 pmRNSDirector Dealings
6th Sep 20177:00 amRNSGrant of first US patent for Chronocort®
6th Sep 20177:00 amRNSResults for the year ended 30 June 2017
14th Aug 201710:00 amRNSNotice of Final Results
15th Jun 20177:00 amRNSFirst Patient Dosed in US Infacort Clinical Trial
18th May 20177:00 amRNSGrant of first US patent for Infacort
8th May 201710:03 amRNSDirector/PDMR Shareholding
27th Mar 20177:15 amRNSHardman Research:Commercial and development update
20th Mar 20177:00 amRNSInterim Results for the 6 Months Ended 31 Dec 2016
16th Mar 20177:00 amRNSLaunch of a European Patient Access programme
2nd Mar 20177:00 amRNSMarketing and Distribution Agreement
1st Mar 20177:00 amRNSNotice of Interim Results
20th Feb 20177:00 amRNSAppointment of Joint Broker
25th Jan 20177:00 amRNSUpdate on Commercial Pre-Launch Activities
19th Jan 20177:15 amRNSHardman Research: Infacort® - On track to market
17th Jan 20173:30 pmRNSDirector Dealings
16th Jan 20177:00 amRNSDirectors' Dealings
12th Jan 20177:00 amRNSAppointment of Chief Financial Officer
4th Jan 20173:38 pmRNSHolding(s) in Company
20th Dec 201612:08 pmRNSSubmission of Infacort® European PUMA Application
23rd Nov 201611:30 amRNSResults of Annual General Meeting
21st Nov 20167:00 amRNSFirst Patient Dosed in Testosterone Trial
9th Nov 20169:36 amRNSDirector/PDMR Shareholding
27th Oct 20167:15 amRNSHardman Research: Get the Rhythm
12th Oct 20167:00 amRNSFull Infacort Phase III Data Analysis
12th Oct 20167:00 amRNSFinal Results June 2016
12th Sep 20167:00 amRNSNotice of Results
11th Jul 20167:00 amRNSPositive headline data Infacort pivotal study
12th Apr 201612:15 pmRNSGrants of options and award of conditional shares
30th Mar 20167:00 amRNSHalf Yearly Report
22nd Mar 20163:00 pmRNSNotice of Results
29th Feb 20167:00 amRNSFirst patient dosed in Chronocort® pivotal study
19th Jan 20163:32 pmRNSHolding(s) in Company
5th Jan 20163:00 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.